Key Highlights

● DexCom reported adjusted Earnings of $0.73 a share against roughly $0.67 to $0.68 expected.

● Revenue rose to $1.344 billion, slightly ahead of the $1.33 billion consensus.

● The company authorized a new $1.0 billion share buyback.

● The 2026 Revenue outlook was set at $5.20 billion to $5.25 billion.

DexCom (NASDAQ:DXCM), the glucose-monitoring company, topped estimates on both lines and authorized fresh share repurchases, lifting the stock in extended trading on Thursday.

Beating on both lines

DexCom delivered a clean quarter after the closing bell on October 29. The maker of continuous glucose monitors, the wearable sensors that let people with diabetes track their blood sugar without finger pricks, reported adjusted earnings of $0.73 a share. That topped the roughly $0.67 to $0.68 analysts had expected.

Revenue rose to $1.344 billion, a double-digit increase from a year earlier and slightly ahead of the $1.33 billion consensus. The stock climbed in extended trading, according to market data, as investors welcomed the combination of growth and discipline.

A $1 billion vote of confidence

The headline-grabbing addition was a new $1.0 billion share buyback. Repurchases reduce the number of shares outstanding and can lift Earnings Per Share over time. Investors often read them as a sign of confidence in the business.

DexCom also set its 2026 revenue outlook at $5.20 billion to $5.25 billion, giving investors a clear framework for the rest of the year.

Medtech's mixed evening

DexCom's gain looked even better next to a fellow medical-device maker. Stryker (NYSE:SYK) tumbled after hours after its results and guidance disappointed. The company's adjusted earnings of $3.52 a share missed the $3.55 consensus, and revenue of $6.5 billion fell short of the $6.62 billion expected. Chief executive Kevin Lobo said the quarter "did fall short of our expectations," while adding that fundamentals "remain strong."

The divergence shows how sharply investors are separating winners from laggards this earnings season. According to market data cited in one news report, 253 S&P 500 companies have now reported, with a large majority beating expectations. Simply beating is no longer enough; the outlook matters just as much.

Health care leads the market

DexCom reported at the end of a strong day for its sector. Health care was the best-performing group in the S&P 500 during the regular session, driven by Eli Lilly (NYSE:LLY), which closed at an all-time high of $1,373.70 after raising guidance, and Merck (NYSE:MRK), which beat estimates and lifted its profit forecast.

The sector's strength was part of a wider rotation. Alphabet (NASDAQ:GOOGL)'s worst day since its 2004 IPO dragged the Nasdaq Composite down 365.13 points to 26,184.72, while more than 400 S&P 500 members rose and the Russell 2000 gained 28.71 points to 2,859.22. Investors favored companies with steady Demand and solid Cash Flow over heavy AI spenders.

"Money is rotating within the market rather than leaving it," said one market strategist, as quoted in market commentary.

Rates and the economy

The macro picture added a layer of caution. Third-quarter GDP grew faster than economists expected, and September PCE Inflation ran hot. The Federal Reserve held rates steady on Wednesday, but two officials, Governor Lisa Cook and Cleveland Fed President Beth Hammack, dissented in favor of a hike.

One Wealth advisor said, "Today's data strengthens the case for another rate increase in December," according to market commentary. Higher rates can weigh on growth stocks, though companies buying back shares with strong cash flow are often seen as better insulated.

What to watch

The first test is Friday's regular session, when full trading Volume will show whether DexCom's after-hours gain sticks. Investors will look for detail on how quickly the buyback will be executed and what is driving the revenue growth.

On the calendar, the third-quarter Employment Cost index arrives Friday, alongside earnings from AbbVie (NYSE:ABBV). The Fed's December 8 to 9 meeting remains the big macro event. For DexCom, the question is whether it can keep beating forecasts while delivering its 2026 revenue range of $5.20 billion to $5.25 billion.